Ohio is currently home to 3190 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Cincinnati, Columbus, Cleveland and Dayton. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas
NCT03715933
Recruiting
This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).
Gender:
ALL
Ages:
Between 12 years and 85 years
Trial Updated:
12/09/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Colorectal Adenocarcinoma, Ewing Sarcoma
Register for Updates
MRI Biomarkers in as Predictor of Clinical Endpoints in Pediatric Autoimmune Liver Disease
NCT03178630
Recruiting
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factor for chronic liver disease among adolescents. This is a longitudinal study to identify surrogate endpoints with an accurate predictive value for the progression of hepatobiliary damage in subjects with pediatric onset AILD. This study will involve collection of MRI-based data at the time of enrollment and at year 1 and 2 of follow up, and collection o... Read More
Gender:
ALL
Ages:
Between 6 years and 23 years
Trial Updated:
12/09/2024
Locations: Cincinnati Children's Hospital and Medical Center, Cincinnati, Ohio
Conditions: Autoimmune Liver Disease, Autoimmune Hepatitis, Primary Sclerosing Cholangitis
Register for Updates
MRI Based Biomarkers in Pediatric Autoimmune Liver Disease
NCT03175471
Recruiting
Autoimmune liver diseases (AILD), which include Primary Sclerosing Cholangitis (PSC) and Autoimmune Hepatitis (AIH) are a common etiological factors for chronic liver disease among adolescents. In all these conditions, autoimmune lymphocyte responses are thought to orchestrate inflammatory injury against hepatocytes (primarily in AIH) or cholangiocytes (in PSC). In this proposal we aim to evaluate the Magnetic Resonance Imaging (MRI) modalities; MR cholangiopancreatography (MRCP) and MR elastogr... Read More
Gender:
ALL
Ages:
Between 6 years and 23 years
Trial Updated:
12/09/2024
Locations: Cincinnati Childrens Hospital Medical Center, Cincinnati, Ohio
Conditions: Autoimmune Liver Disease, Primary Sclerosing Cholangitis, Autoimmune Hepatitis
Register for Updates
Third Party Viral Specific T-cells (VSTs)
NCT02532452
Recruiting
The purpose of this study is to demonstrate that viral specific T-cells (a type of white blood cell) can be generated from an unrelated donor and given safely to patients with viral infections.
Gender:
ALL
Ages:
2 days and above
Trial Updated:
12/09/2024
Locations: Akron Children's Hospital, Akron, Ohio
Conditions: Viral Infection, Viral Reactivation, Infection in an Immunocompromised Host
Register for Updates
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
NCT02143830
Recruiting
The purpose of this study is to determine whether the use of lower doses of busulfan and the elimination of cyclosporine will further reduce transplant-related side effects for patients with Fanconi Anemia (FA). Patients will undergo a transplant utilizing mis-matched related or matched unrelated donors following a preparative regimen of busulfan, fludarabine, anti-thymocyte globulin and cyclophosphamide.
Gender:
ALL
Ages:
3 months and above
Trial Updated:
12/09/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Fanconi Anemia, Severe Marrow Failure, Myelodysplastic Syndrome (MDS), Acute Myelogenous Leukemia (AML)
Register for Updates
Donor-Derived Viral Specific T-cells (VSTs)
NCT02048332
Recruiting
In this research study, the investigators want to learn more about the use of donor-derived viral specific T-cells (VSTs) to treat viral infections that occur after allogeneic stem cell transplant. A viral specific T cell is a T lymphocyte (a type of white blood cell) that kills cells that are infected (particularly with viruses). Allogeneic means the stem cells come from another person. These VSTs are cells specially designed to fight the virus infections that can happen after a bone marrow tra... Read More
Gender:
ALL
Ages:
4 weeks and above
Trial Updated:
12/09/2024
Locations: Akron Children's Hospital, Akron, Ohio
Conditions: Allogeneic Stem Cell Transplant, Viral Infection, Viral Reactivation
Register for Updates
Post-Stroke Sensory Reweighting on Walking and Balance Outcomes
NCT06727097
Recruiting
The primary objective of this proof-of-concept study is to longitudinally track the development of post-stroke sensory reweighting (PSR), identify associated structural neuroanatomical correlates, and investigate their relationship to walking and fall outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: University of Cincinnati College of Medicine, Cincinnati, Ohio
Conditions: Ischemic Stroke
Register for Updates
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
NCT06303505
Recruiting
The purpose of this multicentric, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in patients with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjugate which delivers a topoisomerase I inhibitor to tumor cells which overexpress the target NaPi2b. The study consists of two parts: In dose escalation, ovarian cancer patients and lung cancer patients rece... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Christ Hospital, Cincinnati, Ohio
Conditions: Ovarian Cancer, Non-small Cell Lung Cancer
Register for Updates
Comprehensive Outcomes for After Cancer Health
NCT05349227
Recruiting
This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to participate in a randomized wait-list control study. Those in the intervention group will receive 6 months of digital coaching up front followed by 6 months of ongoing monitoring via patient reported and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Ovarian Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Survivorship, Endometrial Cancer, Head and Neck Cancers, Prostate Cancers, Geriatric Oncology, Metastatic Breast Cancer, Metastatic Cancer
Register for Updates
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
NCT05065736
Recruiting
The purpose of this study is to evaluate whether a new type of imaging study, called 18F-Clofarabine (CFA) PET/CT, can be used to image cancer pyrimidine metabolism in participants. PET (positron emission tomography) imaging is a way of looking at cancers that can reveal cancer metabolism. Presently, however, there are no imaging agents in routine use to look at an aspect of cancer metabolism (pyrimidine metabolism) that dictates whether certain cancer drugs, e.g., gemcitabine, are likely to be... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Metastatic Cancer, Carcinoma, Adenocarcinoma
Register for Updates
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
NCT04614103
Recruiting
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
12/06/2024
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Metastatic Non Small Cell Lung Cancer
Register for Updates
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRĪ±)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT04300556
Recruiting
The primary objectives of the study are: (1) in the dose-escalation part: to evaluate safety and tolerability and to determine the recommended Phase 2 dose (RP2D) of farletuzumab ecteribulin (MORAb-202) in participants with selected tumor types (ovarian cancer \[OC\], endometrial cancer \[EC\], non-small cell lung carcinoma \[NSCLC\], triple-negative breast cancer \[TNBC\]), and (2) in dose-confirmation part: to evaluate preliminary efficacy measured by objective response rate (ORR) of farletuzu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/06/2024
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Solid Tumor
Register for Updates